ACIP Approves and CDC Adopts Pneumococcal, COVID-19 and Meningococcal Vaccine Recommendations

Upcoming Events

Sunflower Health Network Board Meeting - Jan. 9

The Sunflower Health Network is a not-for-profit organization that consists of 26 counties located primarily in North Central and North West Kansas. Sunflower Health Network's (SHN) specific purpose is to improve the population's health status. The 26 member hospitals, in conjunction with their medical staff, have developed a network that fosters cooperation and coordination. The priority has been to enhance the integration of health-related services among the SHN member communities.

Quality Corner Call - Jan. 10

Quality Corner Calls are offered by the Kansas Department of Health and Environment and Healthworks and focus on quality improvement activities consistent with the Medicare Rural Hospital Flexibility Grant Program.

KHA Board Meeting - Jan. 22

KHA has a 21-member board of directors. They meet at least five times a year. Each board member holds three-year terms, with a two-term limit. The board has a composition of members from all geographic areas of Kansas all sizes and types of member hospitals are represented. The board also includes two hospital trustees and two physician members. Other participants include American Hospital Association delegate.

KHA's Advocacy Day - Jan. 23

Advocacy is at the heart of every service KHA provides for our members. Whether we are educating, advocating or relationship-building, we look for ways to assist policymakers at the federal, state and local levels in understanding the implications of the policies being discussed.

KHSC Board Meeting - Jan. 28

KHSC is a wholly owned subsidiary of KHA. Therefore, a secondary objective of KHSC is to support KHA in meeting its mission of serving hospitals. Its mission is to provide enhanced value to KHA members by evaluating and endorsing selected vendors of services needed by the KHA membership. KHSC will be a valuable resource to Kansas healthcare facilities and the Kansas Hospital Association as they serve their constituents.

Current Report Articles

‹‹ Back To List

ACIP Approves and CDC Adopts Pneumococcal, COVID-19 and Meningococcal Vaccine Recommendations

CDC (Nov. 27, 2024) – In its Oct. 23-24, meeting,yhe Centers for Disease Control and Prevention Advisory Committee on Immunization Practices approved several recommendations regarding pneumococcal, COVID-19, and meningococcal vaccines as summarized below:

Pneumococcal Vaccines – ACIP recommends a pneumococcal conjugate vaccine for all PCV-naïve adults aged ≥50 years.

COVID-19 Vaccines – In addition to previously recommended 2024-2025 vaccination:
- ACIP recommends a second dose* of 2024-2025 COVID-19 for adults ages 65 years and older
- ACIP recommends a second dose** of 2024-2025 COVID-19 vaccine for people ages six months-64 years who are moderately or severely immunocompromised
- ACIP recommends additional doses (i.e., 3 or more doses) of 2024-2025 COVID-19 vaccine for people ages six months and older who are moderately or severely immunocompromised under shared clinical decision making
- *If previously unvaccinated and receiving Novavax, two doses are recommended as initial vaccination series followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine six months (minimum interval two months) after second dose
- **If previously unvaccinated or receiving initial vaccination series, at least two doses of 2024-2025 vaccine are recommended, and depending on vaccination history more may be needed. This additional 2024-2025 vaccine dose is recommended six months (minimum interval two months) after completion of initial vaccination series.

Meningococcal Vaccines
- ACIP recommends MenB-4C (Bexsero®) be administered as a two-dose series at birth and six months when given to healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making for the prevention of serogroup B meningococcal disease.
- ACIP recommends MenB-4C (Bexsero®) be administered as a 3-dose series at birth, one-two, and six months when given to persons aged ≥10 years at increased risk for serogroup B meningococcal disease (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to N. meningitidis isolates; and persons at increased risk during an outbreak).

The CDC adopted ACIP's recommendations and they are now official. The official recommendations will be published in CDC’s resources in the coming months, including in MMWR.
--Karen Braman

‹‹ Back To List

Communications

Upcoming Events

Recent News